You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy and Drug Dependence
SBC: KannaLife Sciences Inc. Topic: NIDAChemotherapy induced peripheral neuropathyCIPNcan be a chronicseverely debilitating consequence of cancer therapy for which there are no effective management strategiesMoreoverupwards ofof CIPN patients reported using prescription opioids for pain management despite the fact that there is only weak evidence that long term continuation of opioids provides clinically significant pain relief in these ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
MtLDL detection to diagnose childhood tuberculosis
SBC: CHRONUS PHARMACEUTICALS, INC. Topic: NIAIDProject SummaryChildhood TB is estimated to contributeof the disease burden in high burden settingswith approximately a million cases per year inworldwideExisting gold standard diagnostic culture tools fail to confirm TB in most childrenwho typically have low bacterial counts and cannot produce sputumMore sensitive and child friendly diagnostic tools are urgently needed to diagnose TB in childrenC ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Oxidation-resistant Anti-protease Therapy
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Humanized EMAP II mAb as a Novel Therapy for Viral-Associated Lung Injury
SBC: Allinaire Therapeutics, LLC Topic: NHLBISummary Abstract The ultimate goal of this project is the validation of a humanized endothelial monocyteactivating protein IIEMAP IIneutralizing monoclonal antibodymAbfor progression to clinical evaluation as a novel treatment for patients with influenza associated lung injuryInfection with influenza virusIAVremains a major world wide health threat to high risk populations including the young and ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
3D Holographic Guidance, Navigation, and Control (3D GN&C) for Endovascular Aortic Repair (EVAR)
SBC: CENTERLINE BIOMEDICAL INC Topic: NHLBIProject Summary This project will develop newD visualization to improve stent graft deployment during minimally invasive endovascular aortic repairEVARby overcoming limitations ofD x ray fluoroscopyfluoroD holographic guidancenavigation and controlD GNandamp Cwill be provided to decrease fluoro radiation dose burden to patients and OR staff during treatment of aortic aneurysmsparticularly when dep ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Nucleobase aminosugars with reduced ototoxicity
SBC: NUBAD LLC Topic: YPROJECT SUMMARYAminoglycosides are one of the cheapest and well known antibiotics in clinical use for overyearsbut one of the major limitations in their use is their ototoxicityWe are developing fast and low cost methods to develop aminoglycosides with antiribosomal activities and reduced toxicityIn this projectwe will identify novel aminoglycoside antibacterialsthat show reduced ototoxicityComple ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes
SBC: Cytocybernetics Inc Topic: NHLBIProject Summary As part of the FDA approval process for novel therapeutic drugssafety screening demonstrating that the candidate drug does not have deleterious effects on the human cardiac action potential is requiredHealthy human heart cells are not available for such preclinical drug testingThere is currently no consensus on the best experimental approach to provide the most efficienteconomicala ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Enzymatic attachment of proteins to fluorescent nanodiamond surfaces.
SBC: COLUMBUS NANOWORKS, INC. Topic: 400Fluorescent nanodiamonds are biocompatibleinfinitely photostableand fluoresce in a variety of wavelengthsincluding the near infraredNIRregionThese characteristics suggest transformative applications in areas ranging from pure biological research to biomedical imagingwhere protein conjugated nanodiamonds could be targeted to specific tissues in living patients or even structures within individual c ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
staRt: Enhancing speech treatment with smartphone-delivered biofeedback
SBC: Girlfriends Labs LLC Topic: NIDCDProject Summary Abstract Children with speech sound disorder show diminished accuracy and intelligibility in spoken communication and may thus be perceived as less capable or intelligent than peerseven when they are of average or above average intellectual abilityWhile most speech errors resolve by the late school age yearsup toof individuals will continue to exhibit residual speech errorsRSEthrou ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Imaging Biomarkers of Severe Respiratory Infections in Premature Infants
SBC: KITWARE INC Topic: NHLBIABSTRACTPrematurity is the largest single cause of death in children under five in the world and lower respiratory tract infectionsLRTIare the top cause of hospitalization and mortality in premature infantsClinical tools to predict and prevent severe LRTI in premature pediatric patients are critically needed to allow early interventions to decrease the high morbidity and mortality in this patient ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health